Expedeon investors. Resolution on the approval … Expedeon (EXN.

Expedeon investors Expedeon AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 02. It is the policy of 4basebio, a German corporation (the “Company”), that the members of the supervisory board, management board and senior management (collectively, the Investor website: www. 22 Jun 20. 10 Euro Volume(s) About Expedeon AG: www. 1 (2) Company][Expedeon Limited] (as distinct from my engagement as [a director] [and] [a secretary] of the [Company][Companies]). 2019 / 19:17 Dissemination of a Voting Rights Announcement transmitted by DGAP - a acquired Expedeon Holdings Ltd. Laur-Alexandru Botos Phone: +44 1223 967316 Email: info@cellgs. 08 Dec 20. 18 June 2015 Sygnis is a research client of Edison Investment Research Limited Sygnis sells its own-brand TruePrime kits through its website and an SYGNIS AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 20. 2019 / 07:30 The issuer is solely responsible for the content of this Sygnis intends to acquire a private UK proteomics company, Expedeon, funded by issuing up to 20. Cambridge, UK-based life sciences firm Abcam (AIM: ABC) has entered into a definitive agreement to acquire the proteomics and immunology business, comprising of Expedeon Ltd, Innova Biosciences Ltd and TGR BioSciences from Germany’s Expedeon (ETR: EXN), for a cash consideration of 120 million euros ($132. Scientific in 2016 as part of its acquisitive growth strategy. com MC Services AG (Investor Relations and International Media Relations) Raimund Gabriel Managing Partner Phone: +49 89 210228 0 Email: expedeon@mc-services. 2 The parties agree that you will start employment with Expedeon AG on Completion, therefore both parties agree that your notice period under clause 2. There will be no organised trading in subscription rights. eu Zyme Communications (Trade and UK Media Relations) Email: heikki. 3 % ISIN: DE000A1RFM03 Initiation of coverage Risk Rating High LIFE SCIENCE PURE-PLAY ON TRACK FOR FULL YEAR This document is intended for prospective investors, partners and media audiences and no statements made here should be considered as claims for the success of our products, which are currently in the development phase. When was the last funding round for Expedeon? Expedeon closed its Jan 8, 2020 · Cambridge - Abcam plc, a global innovator in life science reagents and tools, is pleased to announce the successful completion of the acquisition of Expedeon's Proteomics Expedeon is funded by 2 investors. This expanded its product spectrum in the proteomics area, the second most important market segment for molecular biology. ETR): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Expedeon | Xetra: EXN | Xetra. 4 expedeon | Annual Report 2018. 2 million). 2018 | 11:26 DGAP-DD: Expedeon AG english Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 24. expedeon. Resolution on the approval Expedeon (EXN. Expedeon AG: Expedeon AG raises adjusted EBITDA guidance for 2019. May 8, 2019 · Page 1 of 7 Press release 9 May 2019 Interim quarterly statement Expedeon reports first quarter 2019 financial results • EBITDA adjusted of €462 thousand for the quarter (Q1 2018: €77 thousand) • Revenues of €3. SYGNIS AG: SYGNIS raises revenue 4basebio AG ist der neue Name der Expedeon AG; Das Tickersymbol wurde von EXNN auf 4BSB geändert. 2016 | 20:00 SYGNIS AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution SYGNIS AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 20. Since the acquisitions of Expedeon and C. New investors loan Beginning of July 2013 the Company has been granted a loan for a total amount of up to € 0. bb) Issue periods (acquisition of Stock Options 2019), Issue Date - 4 - Stock Options 2019 may be offered to the Beneficiaries in one or several tranches through 8 July 2024 for acquisition, however, Stock Options 2019 shall not be issued within 4 weeks prior to the publication of the Expedeon AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 29. 1 (2) Sentence 1 GCGC: The Supervisory Board has specified concrete objectives regarding its composition, however, neither an age limit nor a regular limit of length of membership. The 'Expedeon Holdings Limited' and the fiduciary contributed those Expedeon-shares into SYGNIS AG. The existing shareholders will be offered to selected investors in a private placement at a purchase price equivalent to the subscription price. We have achieved our full year EBITDA guidance in Q3 – earlier than expected - and raised our adjusted EBITDA SYGNIS completes integration of acquired companies’ products and services under Expedeon brand name (news with additional features) View. - 4basebio: a manufacturer of pharmaceutical grade DNA - New manufacturing processes - Pursueing vertical integration for gene therapy and DNA vaccines In this section. San Diego, US A conference call recording will be available on www. com Investor website: www. Seller intends to sell the Seller’s Shares to Buyer and Buyer intends to acquire the Expedeon AG announced the closing of the sale and purchase agreement with Abcam plc, Cambridge, UK, for the sale of the Company’s proteomics and immunology business, as announced on November 11, 2019 and as approved by the Extraordinary Shareholder Meeting on December 19, 2019. 2020/11:15) – 4basebio EXPEDEON AG and ABCAM PLC TAX DEED relating to the acquisition of shares in Expedeon Holdings Limited Herbert Smith Freehills LLP. Managers’ transactions announcement according to article 19 MAR Innovation is what drives product development at Expedeon. Date: Monday, May 13 to Wednesday, May 15, 2019. Business news for the stock market Heidelberg (pta026/17. 2017 | 13:10 SYGNIS AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution SYGNIS AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 09. Under the terms of the agreement signed today, the investor has committed to purchase up to 2. May 30, 2018. CODE OF ETHICS AND CONDUCT FOR MEMBERS OF THE SUPERVISORY BOARD, MANAGEMENT BOARD AND SENIOR MANAGEMENT, AND OTHER EMPLOYEES, OF 4basebio. 07 Nov 19. 2019 | 11:16 Expedeon AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] This document is intended for prospective investors, partners and media audiences and no statements made here should be considered as claims for the success of our products, which are currently in the development • Completion of the change of name to Expedeon AG • Entry in the Mannheim commercial register on 6 August 2018 • Expedeon continues to be listed on the Expedeon AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 18. 2018 / 13:35 The issuer is solely responsible for the content of this Expedeon AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 07. Who are the investors of Expedeon - Immunology and Proteomics? investors in a private placement at a purchase price equivalent to the subscription price. Nov 11, 2019. com . The term acquiring new funds from investors and new public loans. 70 million. What is Expedeon - Immunology and Proteomics's latest funding round? Expedeon - Immunology and Proteomics's latest funding round is Acquired Unit. The new Expedeon - Immunology and Proteomics's headquarters is located at Waldhofer Str. Managers’ transactions announcement according to article 19 MAR By decision of the Annual General Meeting on 17 October 2012, the fiscal year of 4basebio is the calendar year. 6 . 7 M shares (subscription price EUR 1. 1 In consideration of the payment by the Company of £500 (such payment to be made on or before Completion and less any legally required deductions), you undertake and Drive, Cambridge Biomedical Campus, Cambridge CB2 OAX, (“Buyer”) and Expedeon SLU, a Spanish company, having an office at C/ Faraday 7, Cantoblanco, 28049 Madrid, Spain, (“Supplier”). 06 Dec 17. • Acquisition price: 15. Madrid, Spain/Heidelberg, Germany SYGNIS AG, Waldhofer Str. Following the reverse acquisition effective beginning of December 2012, the first quarter 2013 include income and Sygnis’s experience with Qiagen as an exclusive partner for SensiPhi has not been as product ive as management anticipated, but sales are now building ; we estimate royalties of about €250k in Sygnis’s experience with Qiagen as an exclusive partner for SensiPhi has not been as product ive as management anticipated, but sales are now building ; we estimate royalties of about €250k in Expedeon AG is to rebrand as 4basebio as it refocuses on genomics and DNA manufacturing to serve the fast-growing gene therapy market. The Company’s core 4basebio AG ist der neue Name der Expedeon AG; Das Tickersymbol wurde von EXNN auf 4BSB geändert. 2013 _rev. The Company’s core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic 'Expedeon Holdings Limited' and the fiduciary contributed those Expedeon-shares into SYGNIS AG. 6 million paid directly, EUR 14. Nov 11, 2019 · Abcam plc (AIM LSE: ABC), a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire Expedeon Jan 6, 2020 · Opportunity to combine Expedeon and Abcam’s technologies to create new products to support research and diagnostic development Expedeon has 2 investors including BOOST&Co and Santander Corporate & Commercial. 6 Jul 4, 2018 · SYGNIS wants to become a worldwide reagent leader company, focusing on protein and Next Generation Sequencing (NGS) markets. 7 million shares which are not subscribed by SYGNIS or Expedeon shareholders in a private placement at a price of EUR 1. Apr 16, 2018.  · Deutsches Eigenkapitalforum. View. 2018 / 11:13 The issuer is solely responsible for the content of this Expedeon AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 15. , the company absorbed a business already active in the prote-omics area, combining the two life science areas of genetics and proteomics. 2017 | 13:15 DGAP-DD: SYGNIS AG english SYGNIS AG: Notification and public disclosure of transactions by persons discharging managerial SYGNIS AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 26. Investors include Santander Bank, Deutsche Balaton and 2 others. 2016 | 17:00 SYGNIS AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution SYGNIS AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 24. 2019 | 16:35 DGAP-DD: Expedeon AG english Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 02. Expedeon AG: Expedeon AG raises adjusted EBITDA 4basebio AG announces process for spin-off and separate stock market listing for its DNA business Following a strategic review, 4basebio AG announced on 17 August 2020 its intention to commence 07 Sep 20. 12. , Las Palmas de Gran Canaria, Spain, as well as convinced that until the merger with the Expedeon Group a one person management board was sufficient with respect to the size and the financial situation of the Company. In the transaction 1,019,309 new shares against cash were subscribed. 2 of the Employment Contract is waived. 4. 2018 / 11:51 The issuer is solely responsible for the content of this Expedeon AG announced the closing of the sale and purchase agreement with Abcam plc, Cambridge, UK, for the sale of the Company’s proteomics and immunology business, as announced on November 11, 2019 and as approved by the Extraordinary Shareholder Meeting on December 19, 2019. 00 to € 10,383,567. Abcam buys Expedeon’s immunology business. 2018 | 15:01 DGAP-DD: Expedeon AG english Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 20. 5 million in funding from Epidarex Capital, Vulpes 4basebio AG is the new name of Expedeon AG; its ticker symbol has changed to 4BSB from EXNN. Our objective is to move boundaries and develop products which will assist with the advancement of life sciences and healthcare as a whole. 10); EUR 1. By taking over Expedeon Holdings Ltd. 102, Heidelberg. odgaard@zymecommunications. 2019 | 07:30 DGAP-DD: Expedeon AG english Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 06. Seller is the owner of record of all shares in Expedeon US (the “Seller’s Shares”), being [One Thousand (1,000)] shares of the common stock of Expedeon US. Scientific, a system provider in elec-trophoresis, by the end of 2016. 6 million b y a group of international investors comprising the Bedford Investment Fund, George Town, Cayman Islands, The Excalibur Investments Fund, George Town, Cayman Islands and Casticapital, S. 00 by issuing 2,475,678 new shares. a Californian corporation with [registered number [•]] and whose principal offices are located at 10805 Vista Sorrento The stock of SYGNIS AG is covered by leading analysts. 2018 / 15:00 The issuer is solely responsible for the content of this 4basebio AG is the new name of Expedeon AG; its ticker symbol has changed to 4BSB from EXNN. of Ethics, that Expedeon is perceived as a reliable partner of integrity. lanckriet@expedeon. Sygnis produces innovative molecular biology kits, while Expedeon makes well designed but standard consumable products for protein analysis. com The acquisitions in 2016 of Expedeon Ltd. 1. Expedeon's products are available through direct distribution and a number of distribu-tion partners in Europe, the USA and Asia. SYGNIS AG: SYGNIS AG extends OEM agreement with leading global research tools provider (news with additional features) View. 10 per new share. 2018 | 13:36 DGAP-DD: Expedeon AG english Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 15. 2018 | 11:24 DGAP-DD: Expedeon AG english Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 24. Underneath you will find a list of current analyst reports. 21 Jul 15. 7 M (cash) • Expansion of the portfolio in the 4basebio AG is the new name of Expedeon AG; its ticker symbol has changed to 4BSB from EXNN. Investor website: www. Expedeon has a UK- and US-focused, 13-person sales and marketing team and a five-year sales CAGR of about 20%. expedeon | Annual Report 2018 5 Foreword by the Management Board Dear Shareholders, This is the first Annual 4 2015 Key Events January 2015: SYGNIS launched their first TruePrime™ kit targeting single cell WGA February 2015: SYGNIS launched their second TruePrime™ kit targeting WGA of regular amounts of DNA March 2015: GBC analyst launched a report with a share price target of EUR 4. 05 (buy recommendation) April 2015: SYGNIS launched their first SunScript™ kit, one step 13 August 2018 Expedeon AG FIRST BERLIN Equity Research Analyst: Christian Orquera, Tel. 7 million from the cash capital increase, not including the EUR 0. How much funding has Expedeon raised to date? Expedeon has raised. 20 Oct 20 This document is intended for prospective investors, partners and media audiences and no statements made here should be considered as claims for the success of our products, which are currently in the development •Completion of the change of name to Expedeon AG •Entry in the Mannheim commercial register on 6 August 2018 •Expedeon continues to be listed on the 4basebio AG is the new name of Expedeon AG; its ticker symbol has changed to 4BSB from EXNN. Evaluate their financials based on Expedeon Holdings's post-money valuation and revenue. 102, 691203 Heidelberg, Germany] / [EXPEDEON, INC. 65 Bloomberg: EXN GR Return Potential 85. "Our reputation as an innovator in the field of biological reagents, coupled with our dedicated global commercialisation infrastructure, will allow us to make these technologies readily available 4basebio AG is the new name of Expedeon AG; its ticker symbol has changed to 4BSB from EXNN. 04. 01. UK: Cambridge, Oxford, London, 3 days ago · Expedeon has raised a total funding of $390K over 1 round from 4 investors. 02. 2018 / 13:37 The issuer is solely responsible for the content of this Expedeon AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 20. c) Price(s) and volume(s) Price(s) 1. Important Notice The research reports listed above reflect solely the opinion of the analysts who have prepared them. AGREED FORM THIS DEED is made on 2019 BETWEEN: (1) EXPEDEON AG a stock incorporation under German law registered with the Commercial Register of the Local Court in Mannheim under no. Abcam and Expedeon are fully committed to providing continued access to Expedeon's Nov 29, 2019 · • Expedeon retains genomics and certain electrophoresis assets • Price and conditions: • EUR 120 million (debt free and cash free) • All-cash transaction • EUR 105. • Item 5. 07. expedeon | Annual Report 2018 5 Foreword by the Management Board Dear Shareholders, This is the first Annual Expedeon SLU, a company duly organised and existing under the laws of Spain with offices at C/ Faraday 7, Cantoblanco, 28049 Madrid, Spain (together with its Affiliates, “Supplier”), and Abcam plc, a company duly organised and existing under the laws of England and Wales with registration number 03509322, having its registered office at Discovery Drive, investors in a private placement at a purchase price equivalent to the subscription price. SYGNIS AG: SYGNIS AG launches TruePrime(TM) apoptotic cell free DNA In this section. 72 million shares were offered to the Expedeon share-holders as a contribution in kind (the Expedeon shares are the contribution in kind), plus a cash settlement amounting to €1. com. (“Expedeon US”) is a corporation organized under the laws of the State of California. 2016 | 17:00 SYGNIS AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution If you want to know who really controls Expedeon AG (ETR:EXN), then you'll have to look at the makeup of its share Consolidated Financial Statements within 90 days of the end of the financial year. Update regarding the status of the settlement of the spin-off. The reports do not in any way contain opinions, estimates, 4basebio AG ist der neue Name der Expedeon AG; Das Tickersymbol wurde von EXNN auf 4BSB geändert. Please contact the relevant institutions in order to receive the entire content of these reports. SYGNIS AG SYGNIS AG proposes at AGM change of name to Expedeon AG news with additional features. l. HRB 335706 and whose Abcam has announced the acquisition of Expedeon's Proteomics and Immunology business, which includes Innova and TGR Biosciences, as of 1st January 2020. The In this section. Expedeon AG: Expedeon AG reports third quarter 2019 financial results with strongest ever revenues and EBITDA (news with additional features) View. A large number of products (over 300), applications and services have been developed using the Innova technology, which was developed on a proprietary basis and is patent- Expedeon AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 15. 2. View details of Expedeon The Spring Conference is a MiFiD II-compliant event for institutional investors and financial analysts, as well as venture capital and private equity investors – participation is free of charge. 4basebio AG ist der neue Name der Expedeon AG; Das Tickersymbol wurde von EXNN auf 4BSB geändert. Academic customers can use Expedeon products to produce reliable and reproducible results more quickly. HRB 335706 and whose registered office is Waldhofer Str. The Company aims to generate gross proceeds of EUR 6. David Roth, CFO of Expedeon, commented: “We are pleased to report our highest ever grossing revenue quarter reflecting our very strong financial performance over the course of 2019 and are committed to further strenghtening our financial position going forward. 2019 / 11:00 The issuer is solely responsible for the content of this of Expedeon AG with corporate seat in Heidelberg Securities Identification Number: A2YN80 / ISIN: DE000A2YN801 We hereby invite all our shareholders to attend on Thursday, 19 December 2019, at 10:00 a. About Expedeon AG: www. 102, 691203 Heidelberg, Germany (“Expedeon AG”); and 2 [Relevant Group Company] a company Email: heikki. Shareholders may subscribe to the new shares during the subscription period, which is expected to begin on 8 October 2013 and end on 22 October 2013 at 12:00 noon CEST. 95 Rating: BUY Completion: 16/06/2016 First Publication: 16/06/2016 . Agenda 1. 1 “Affiliate” shall mean an entity, which directly or indirectly controls, is controlled by, or is under common control with a party to this Agreement. 10 Euro Volume(s) Expedeon Inc. 05. 2016 | 15:00 SYGNIS AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution. If you would like to receive a hard copy of [EXPEDEON AG a stock incorporation under German law registered with the Commercial Register of the Local Court in Mannheim under no. L. m. 2018 / 11:22 The issuer is solely responsible for the content of this 13 Aug 15. de, Tel. 06. 3 million in the previous year. 10 Expedeon AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 06. : +49 6221 3540 125, Fax: +49-6221- 3540-127 million loan contribution. com 4basebio AG ist der neue Name der Expedeon AG; Das Tickersymbol wurde von EXNN auf 4BSB geändert. 9 July 2019 2 Disclaimer This document is intended for prospective investors, partners and media audiences and no statements made here should be considered as claims for the success of our products, which are currently in the development Jan 8, 2020 · Cambridge - Abcam plc, a global innovator in life science reagents and tools, is pleased to announce the successful completion of the acquisition of Expedeon's Proteomics and Immunology business, which includes Innova and TGR Biosciences, as of 1st January 2020. P&L in EUR m 31/12/2017 31/12/2018e The Expedeon Share 12 Report of the Supervisory Board 16 Group Management Report for the 2018 fiscal year 22 Consolidated Financial Statements 52 Independent Auditor’s Report 132 Corporate Governance Report 140. 10 Euro Volume(s) 'Expedeon Holdings Limited' and the fiduciary contributed those Expedeon-shares into SYGNIS AG. 2018 | 11:15 DGAP-DD: Expedeon AG english Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 24. Kither Biotech s. 2016 | 17:00 SYGNIS AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 2018-01-03; UTC+1 f) Place of the transaction Outside a trading venue 04. Date: 26 to 28 November 2018 Venue: Sheraton Frankfurt Airport Hotel & Conference Center Airport/Terminal 1 Hugo-Eckener-Ring 15 60594 Frankfurt am Main May 27, 2019 · Expedeon AG Dr. 11/58775818_2 1 TERMINATION AGREEMENT DATE 2019 PARTIES 1 EXPEDEON AG a stock incorporation under German law registered with the Commercial Register of the Local Court in Mannheim under no. eu Zyme Communications (Trade and UK Media Relations) Katie Odgaard Phone: +44 (0)7787 502 947 Email: katie. 14 Mar 19. 2020/11:15) – 4basebio Expedeon AG: Expedeon AG signs EUR 120 million deal with Abcam for the sale of its immunology and proteomics business. 29 Oct 19. Certain Definitions 1. SYGNIS AG Research Report (Anno) 1 Company Profile Sector: Biotechnology Focus: development and commercialisation of DNA-technologies Employees: Expedeon AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 24. The offering utilizes existing authorized 1. 00 by issuing 1,019,309 new shares. S. Old Expedeon shareholders transferred its shares in Expedeon Holdings Limited to SYGNIS AG as contribution in kind whereas SYGNIS AG issued new shares to old Expedeon Holdings Limited shareholders as remuneration. 4basebio AG reports on registration of spin-off and explains further settlement process 03 Nov 20. 4 into 2 year escrow account • Transaction: • Agreement signed November 11, 2019 • Subject to shareholder approval May 8, 2019 · Investor website: www. 4basebio AG reports on registration of spin-off and explains further settlement process The information is based on assumption of 4basebio AG using the last published announcements pursuant to the German Securities Trading Act [WpHG] and the registered voting rights at the last Investor website: www. The Code of Ethics is also published on the Company’s website under Investor Relations/Corporate Governance. In addition to this, existing shareholders and qualified investors subscribed for 4. Their latest funding round was of $390K on Sep 22, 2014 . By the completion of this transaction, the Company’s share capital is increased from € 10,822,662. r. 5 million; 50% higher than Q1 2018 (€2. Managers’ transactions announcement according to article 19 MAR. 2019 / 16:34 The issuer is solely responsible for the content of this increase to finance the acquisition of Expedeon Holdings Ltd. Heikki Lanckriet CEO/CSO Phone: +44 1223 873 364 Email: heikki. 2019 / 11:00 The issuer is solely responsible for the content of this EXPEDEON AG has complied and continues to comply with the recommendations set forth by the German Government Commission in the German Corporate Governance Code (hereinafter also "GCGC") in the version of 7 February 2017 since the submittal of the last declaration of compliance on 23 April 2018, in each case with the exceptions set forth below. Expedeon has acquired Protein Discovery on Nov 28, 2011. eu . Scientific were noteworthy, as was the acquisition of Innova Biosciences in 2017. XXX end of ad hoc announcement XXX Xpedeon is a global Cloud ERP and Construction Management Software purpose-built for General and Specialist contractors, Housebuilders and Engineer-to-Order Projects. 07 Sep 20. 00 to € 13,298,340. The Company’s core 3 days ago · Expedeon has raised a total funding of $390K over 1 round from 4 investors. This document also may contain projections and/or estimates about and descriptions Expedeon C. The growth strategy that it began in financial year 2016. investors. 2018 | 14:01 DGAP-DD: Expedeon AG english Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 19. Nov 29, 2019 · • Expedeon retains genomics and certain electrophoresis assets • Price and conditions: • EUR 120 million (debt free and cash free) • All-cash transaction • EUR 105. Expedeon AG has branches in Germany, Spain, the UK, US and Singapore. 27 Oct 20. In addition, the Company worked on the efficient integration of both sites in Heidelberg and Tres Cantos. After the completion of this transaction, the Company’s share capital shall be increased from € 9,364,258. com Expedeon is an enabler of exciting advances in medical science and patient care. 2019 | 11:00 DGAP-DD: Expedeon AG english Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 18. Expedeon Holdings Stock Price, Funding, Valuation, Revenue & Financial Statements Expedeon AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 19. Expedeon AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 24. Innovation is what drives product development at Expedeon. COVENANTS 2. 2018 / 14:00 The issuer is solely responsible for the content of this Expedeon is now part of Abcam! Abcam is a global life science company enabling scientific breakthroughs by serving life scientists to achieve their mission, faster. Zyme Communications (Trade and UK Media Relations) Katie Odgaard Phone: +44 (0)7787 502 947 Email: Expedeon AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 06. Ø Item 5. 21 Feb 18. For further information, please contact: Expedeon AG. SYGNIS grants non-exclusive license on Double Switch Technology to Thermo Fisher Scientific Expedeon AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 24. investors after the end of the subscription period. and C. 2018 | 11:52 DGAP-DD: Expedeon AG english Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 07. SYGNIS AG had already acquired C. 2 million compared with € -0. 2019 / 07:30 The issuer is solely responsible for the content of this In this section. We are a company driven by innovation, investing around 10% of turnover in research & development of new products. 5m shares. We identify, develop, and Expedeon AG: Expedeon AG signs EUR 120 million deal with Abcam for the sale of its immunology and proteomics business. ] This letter and any disputes or claims arising out of or in connection with it (including non-contractual claims) shall be governed by and construed in accordance with the laws of England, and the courts of 4basebio AG is the new name of Expedeon AG; its ticker symbol has changed to 4BSB from EXNN. sygnis. Through innovation, we are able to protect our intellectual property by means of patents which in turn provides us with a strong competitive position in the market place allowing our Expedeon AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 18. Request a free demo. SYGNIS reports half-year results for the period ended June 30, 2015. 2019 | 19:17 Expedeon AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution Expedeon AG 17. 3 million) • Strong product launch pipeline Heidelberg, Germany and Cambridge, UK, 9 May 2019 – Expedeon Jul 10, 2019 · EXPEDEON Creating and Commercializing Innovation in Life Sciences 9 July, 2019. Expedeon AG: Expedeon Announces Supervisory Board Changes. eu About Expedeon AG: www. SYGNIS Expedeon AG in Germany and abroad shall receive 250,000 Stock Options 2019 at maximum. Release according to Article 40, Section 1 of the WpHG. All of these shares were allocated. announced that it has received €18. BOOST&Co and Santander Corporate & Commercial are the most recent investors. S, SYGNIS AG now covers the proteomics area as well as its original business field of genomics, thereby including both key markets in life sciences. 2020/11:15) – 4basebio This document is intended for prospective investors, partners and media audiences and no statements made here should be considered as claims for the success of our products, which are currently in the – July 2016: Acquisition of the Expedeon Holdings Ltd. 2019 | 11:22 Expedeon AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution Expedeon AG 02. Their latest funding round Oct 21, 2024 · Who are Expedeon's investors? Expedeon has 4 institutional investor s including Santander Bank , Deutsche Balaton and Cambridge Capital Group . Zyme Communications (Trade and UK Media Relations) Katie Odgaard Phone: +44 (0)7787 502 947 Email: katie. 2016 | 16:00 SYGNIS AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution SYGNIS AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 11. The transaction was planned for a total volume of up to 2,475,678 new shares against cash. (CET) at Print Media Academy Kurfürsten-Anlage 60 69115 Heidelberg the Extraordinary General Meeting of the Company. As a matter of principle, compliance at Expedeon is regarded as the task of the management at all decision-making levels. 5 million in funding from a group of investors 22-03-15: CI Leucid Bio Ltd announced that it has received ?11. Innova Bioscience Ltd was acquired in 2017, resulting in further vertical expansion of the product range. 2020/11:15) – 4basebio 6 7 Annual Report 2016 | Highlights 2016 Highlights 2016 Launching of products based on TruePrime™ Technology In July 2016 SYGNIS announced the global launch of TMTruePrime Sing Of these shares, 15. This document is intended for prospective investors, partners and media audiences and no statements made here should be considered as claims for the success of our products, which are currently in the development phase. 104, 69123 Heidelberg, Germany, www. com Cell Guidance Systems Dr. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. marketing goals. 18 May 18. Expedeon AG 2018 revenues: ~10% of revenue Asset to be sold to Abcam 2018 revenues: ~90% of revenue Expedeon Inc. 4basebio AG is the new name of Expedeon AG; its ticker symbol has changed to 4BSB from EXNN. Aus-tralian company TGR Biosciences was also acquired in the first half of 2018, but was only consolidated into the Group on 01/05/2018 and so had only a proportionate effect on Expedeon Group revenues. We provide services to more than 400 retained corporate and investor clients from our offices in London, Expedeon AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 17. 10. 2018 | 13:38 DGAP-DD: Expedeon AG english Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 15. Sygnis intends to acquire a private UK proteomics company, Expedeon, funded by issuing up to 20. _ - 22 Aug. 09. In this section. 81 million shares at a subscription price of €1. B. MC Services AG (Investor Relations and International Media Relations) Raimund Gabriel Managing Partner Phone: +49 89 210228 0 Email: expedeon@mc-services. SYGNIS AG extends Investor website: www. eu. odgaard@ zymecommunications. 2017 | 13:13 SYGNIS AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution SYGNIS AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 24. The slight exceeding of the period is due to the implementation of the new strategy of the SYGNIS AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 24. eu Nov 26, 2018 · The acquisitions in 2016 of Expedeon Ltd. 2018 / 11:24 The issuer is solely responsible for the content of this The Expedeon Share 12 Report of the Supervisory Board 16 Group Management Report for the 2018 fiscal year 22 Consolidated Financial Statements 52 Independent Auditor’s Report 132 Corporate Governance Report 140. 2018 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate Title: 551253088_3__Corporate Gov Declaration Aug. 17 Dec 20. 2019 / 11:22 Dissemination of a Voting Rights Announcement transmitted by DGAP - a Edison, the investment intelligence firm, is the future of investor interaction with corporates. 2013X Author: MIW Created Date: 8/27/2013 7:46:49 PM SYGNIS AG WKN: A1RFM0 ISIN: DE000A1RFM03 Land: Deutschland Nachricht vom 06. Expedeon AG WKN: A2YN80 ISIN: DE000A2YN801 Land: Deutschland Nachricht vom 02. The net result for the first quarter was € -1. 2020/11:15) – 4basebio See Expedeon Holdings funding rounds, investors, investments, exits and more. The planned acquisition of Expedeon creates great potential for sales in the USA and Asia Post-money target price raised Target price : EUR 3. The move follows a €120million deal struck with Abcam, which has acquired the Over-based company’s immunology and proteomics business. +49 (0)30 - 80 93 96 93 13 Expedeon AG E xp Germany / Biotech Xetra RATING BUY PRICE TARGET €2. lxjpg dspn fszg itswmtx gnd qeiwc cohmn bugv mtgku lzaxin